ISSN: 1308-5727 | E-ISSN: 1308-5735
Volume: 15 Issue: 2 Year: 2023
Forms

Abstracting & Indexing
Turkish Society for Pediatric Endocrinology and Diabetes
Endocrinological Approach to Adolescents with Gender Dysphoria: Experience of a Pediatric Endocrinology Department in a Tertiary Center in Turkey [J Clin Res Pediatr Endocrinol]
J Clin Res Pediatr Endocrinol. Ahead of Print: JCRPE-96158 | DOI: 10.4274/jcrpe.galenos.2023.2023-1-13

Endocrinological Approach to Adolescents with Gender Dysphoria: Experience of a Pediatric Endocrinology Department in a Tertiary Center in Turkey

Esin Karakilic Ozturan1, Ayse Pinar Ozturk1, Firdevs Bas1, Ayse Burcu Erdogdu2, Seven Kaptan3, Asli Derya Kardelen Al1, Sukran Poyrazoglu1, Melek Yıldız1, Neşe Direk4, Sahika Yuksel5, Feyza Darendeliler1
1Istanbul University, Istanbul Faculty of Medicine, Department of Pediatrics, Pediatric Endocrinology Unit
2Marmara University Pendik Training and Research Hospital, Department of Child and Adolescent Psychiatry Unit
3Psychiatrists in Private Practice
4Istanbul University, Istanbul Faculty of Medicine, Department of Psychiatry
5Istanbul University, Istanbul Faculty of Medicine, Department of Psychiatry, Emeritus Professor, Psychiatrist in Private Practice

INTRODUCTION: Objective: A significant rise in the number of trans adolescents seeking medical interventions has been reported in recent years. In this study, we aimed to report the clinical features, treatment, and follow-up of adolescents with gender dysphoria (GD) with our increased experience.
METHODS: Methods: Twenty-six male-to-female (MTF) and twenty-seven female-to-male (FTM) adolescents who were referred to our GD-outpatient clinic between the years 2016 and 2022 were reviewed. The clinical and laboratory findings of thirty transgender adolescents (15FTM /15 MTF) who received medical intervention were evaluated retrospectively.
RESULTS: Results: The vast majority of individuals (60.4%) were admitted between 2020 and 2022, and the remaining (39.6%) were admitted between 2016 and 2019. At the referral time, median age was 16.3 years (IQR,1.53; range, 13.2-19.4) in 26 MTF, and 16.4 years (IQR,1.74; range, 11.7-21.6) in 27 FTM adolescents. The median age of the pubertal blockage with gonadotropin-releasing hormone analog (GnRHa) and androgen receptor blocker was 16.4 years (IQR,1.4; range, 11.7- 17.8) in 22 adolescents (9 MTF,13 FTM), and 17.4 years (IQR,1.4; range, 15.5-19.4) in 6 MTF individuals, respectively. The cross-sex hormone therapy (CSH) was commenced in 21 adolescents (12 MTF, 9 FTM) at the median age of 17.7 years (IQR,0.61; range,16-19.5). Fifteen individuals (8 MTF, 7 FTM) have been transferred to the adult endocrinology department in transition clinics.
DISCUSSION AND CONCLUSION: Conclusion: All treatments were well tolerated and effective including bicalutamide, no side effects were observed. Besides, transition clinics play an important role in the better management of gender reassignment processes.

Keywords: Transgender, gender reassignment, gonadotropin-releasing hormone treatment, bicalutamide, cross-sex hormone, transition, multidisciplinary followup



Corresponding Author: Esin Karakilic Ozturan, Türkiye
Manuscript Language: English
LookUs & Online Makale